Barclays Reaffirms Their Buy Rating on Rio Tinto (RIO)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fletcher covers the Basic Materials sector, focusing on stocks such as Rio Tinto, BHP Group Ltd, and Vale SA. According to TipRanks, Fletcher has an average return of 0.9% and a 54.37% success rate on recommended stocks.
In addition to Barclays, Rio Tinto also received a Buy from TR | OpenAI – 4o's Gavin Steelwright in a report issued yesterday. However, on the same day, RBC Capital maintained a Hold rating on Rio Tinto (LSE: RIO).
Based on Rio Tinto's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p26.86 billion and a net profit of p5.74 billion. In comparison, last year the company earned a revenue of p27.37 billion and had a net profit of p4.94 billion
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RIO in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
9 hours ago
- Globe and Mail
Tyler Technologies (TYL) Receives a Rating Update from a Top Analyst
In a report released today, Trevor J. Walsh from Citizens JMP reiterated a Buy rating on Tyler Technologies, with a price target of $700.00. The company's shares closed yesterday at $584.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. J. Walsh covers the Technology sector, focusing on stocks such as Zscaler, CyberArk Software, and Cloudflare. According to TipRanks, J. Walsh has an average return of 31.3% and a 73.23% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tyler Technologies with a $672.56 average price target, representing a 15.05% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $708.00 price target. TYL market cap is currently $25.29B and has a P/E ratio of 83.59. Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TYL in relation to earlier this year. Most recently, in June 2025, Brian K. Miller, the EVP & CFO of TYL sold 1,200.00 shares for a total of $696,857.01.
Globe and Mail
11 hours ago
- Globe and Mail
D.A. Davidson Sticks to Its Buy Rating for Amazon (AMZN)
In a report released today, Gil Luria from D.A. Davidson maintained a Buy rating on Amazon, with a price target of $265.00. The company's shares closed yesterday at $234.11. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Luria is a 5-star analyst with an average return of 16.1% and a 60.74% success rate. Luria covers the Technology sector, focusing on stocks such as Adobe, CoreWeave, Inc. Class A, and ServiceNow. Amazon has an analyst consensus of Strong Buy, with a price target consensus of $262.55, a 12.15% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $255.00 price target. AMZN market cap is currently $2485.4B and has a P/E ratio of 38.18.
